CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 33 enrolled
Drug / intervention
pembrolizumabdrug
Likely dose
pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02434354
NCT02434354Phase 1Completed
CompareCT.gov

A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Abramson Cancer Center at Penn Medicine·interventional·Posted May 5, 2015·Updated Jun 16, 2022

In Brief

A Phase 1 clinical trial evaluating pembrolizumab for Malignant Melanoma. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The main purpose of this trial is to evaluate the safety, tolerability and adverse event profile of pembrolizumab in subjects who have high risk melanoma before and after their standard of care surgical resection, and to collect tumor tissue from subjects before and after receipt of pembrolizumab to look at how the experimental drug interacts with tumor tissue. Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 5, 2015
Enrollment StartApr 1, 2015
Primary CompletionJul 1, 2019
Study CompletionSep 29, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.2 years ago

Interventions

pembrolizumabdrug

200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab